For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Attruby represents a genuine advancement . These novel therapies protect the transthyretin protein, slowing its harmful build-up and alleviating the impact of the il